Difference between revisions of "Team:SYSU-MEDICINE/Integrated Practices"

 
Line 340: Line 340:
 
     <div class="my-content">
 
     <div class="my-content">
 
         <p>
 
         <p>
             Human Practices group has been one of the critical parts of the project since the very beginning. Unlike experiment group, Human Practices concern more about bringing the experimental result to reality application.<br/>
+
             Human Practices group has been one of the critical parts of the project since the very beginning. Unlike experiment group, Human Practices concerns more about bringing the experimental results to real life.<br/>
 
             <br/>
 
             <br/>
             At the beginning of the project, HP tried to find out whether MSCs is really effective in clinical using. We <a href="https://2016.igem.org/Team:SYSU-MEDICINE/Interview#doctor" target="_blank">interviewed patients and doctors</a> in order to know the effect and their attitude towards MSCs therapy, the result showed that MSCs do have effectiveness but limited, which means MSCs cannot replace the regular anti-inflammatory medicine but have advantages in combination with medication. In consideration of this situation, we put up the possibility of enhancing the effectiveness of MSCs and then had <a href="https://2016.igem.org/Team:SYSU-MEDICINE/Interview#pi" target="_blank">a further talk with our PI.</a><br/>
+
             At the beginning of the project, HP tried to find out whether MSCs were really effective in clinical application. We
             <a href="https://2016.igem.org/Team:SYSU-MEDICINE/Interview" target="_blank">More</a>.<br/>
+
            <a href="https://2016.igem.org/Team:SYSU-MEDICINE/Interview#doctor" target="_blank"><b><u><font color="#e57d22">interviewed patients and doctors</b></u></font></a> in order to know their attitudes towards MSCs therapy. The results showed that MSCs do have effectiveness but limited, which means MSCs cannot replace the regular anti-inflammatory medicine but have advantages in combination with medication. In consideration of this situation, we put up an idea of enhancing the effectiveness of MSCs and then had
 +
            <a href="https://2016.igem.org/Team:SYSU-MEDICINE/Interview#pi" target="_blank"><b><u><font color="#e57d22">a deeply talk with our PIs.</b></u></font></a><br/>
 +
             <a href="https://2016.igem.org/Team:SYSU-MEDICINE/Interview" target="_blank"><b><u><font color="#e57d22">More</b></u></font></a>.<br/>
 
             <br/>
 
             <br/>
             During medium phage of the project, we devote ourselves to study and investigate other aspects connected to our project including
+
             During mid phage of our project, we devoted ourselves to study and investigate other aspects connected to our project including
             <a href="https://2016.igem.org/Team:SYSU-MEDICINE/Ethics" target="_blank">ethics</a>,
+
             <a href="https://2016.igem.org/Team:SYSU-MEDICINE/Ethics" target="_blank"><b><u><font color="#e57d22">ethics</b></u></font></a>,
                 <a href="https://2016.igem.org/Team:SYSU-MEDICINE/Legislation" target="_blank">law and legislation</a>,
+
                 <a href="https://2016.igem.org/Team:SYSU-MEDICINE/Legislation" target="_blank"><b><u><font color="#e57d22">law and regulation</b></u></font></a>,
                     <a href="https://2016.igem.org/Team:SYSU-MEDICINE/Safety" target="_blank">safety</a>,
+
                     <a href="https://2016.igem.org/Team:SYSU-MEDICINE/Safety" target="_blank"><b><u><font color="#e57d22">safety</b></u></font></a>,
                         <a href="https://2016.igem.org/Team:SYSU-MEDICINE/Products" target="_blank">product analysis</a> including intellectual property rights and so on by literature studying, interview and questionnaire, attending Cell Therapy Annual Meeting etc.<br/>
+
                         <a href="https://2016.igem.org/Team:SYSU-MEDICINE/Products" target="_blank"><b><u><font color="#e57d22">product analysis</b></u></font></a> including intellectual property rights and so on by literature studying, interview and questionnaire, attending Cell Therapy Annual Meeting, etc.<br/>
 
             <br/>
 
             <br/>
 
             Time flies. It is almost the end phage of the project this year, but we don't want to stop here. We can do more and better! We have done a lot of researches and had many activities during the project and we admit that there is such a large room for us to improve. We have no time to finish them in this year but we draw a discussion of
 
             Time flies. It is almost the end phage of the project this year, but we don't want to stop here. We can do more and better! We have done a lot of researches and had many activities during the project and we admit that there is such a large room for us to improve. We have no time to finish them in this year but we draw a discussion of
             <a href="https://2016.igem.org/Team:SYSU-MEDICINE/Our_Story#improvement" target="_blank">Room for Improvement</a> for the teams next year.<br/>
+
             <a href="https://2016.igem.org/Team:SYSU-MEDICINE/Our_Story#improvement" target="_blank"><b><u><font color="#e57d22">Room for Improvement</b></u></font></a> for the teams next year.<br/>
 
             <br/>
 
             <br/>
             Get more information from <a href="https://2016.igem.org/Team:SYSU-MEDICINE/Our_Story" target="_blank">our story</a> page.  <br/>
+
             Get more information from <a href="https://2016.igem.org/Team:SYSU-MEDICINE/Our_Story" target="_blank"><b><u><font color="#e57d22">our story</b></u></font></a> page.  <br/>
  
 
         </p>
 
         </p>

Latest revision as of 22:39, 19 October 2016

Integrated Human Practices

Human Practices group has been one of the critical parts of the project since the very beginning. Unlike experiment group, Human Practices concerns more about bringing the experimental results to real life.

At the beginning of the project, HP tried to find out whether MSCs were really effective in clinical application. We interviewed patients and doctors in order to know their attitudes towards MSCs therapy. The results showed that MSCs do have effectiveness but limited, which means MSCs cannot replace the regular anti-inflammatory medicine but have advantages in combination with medication. In consideration of this situation, we put up an idea of enhancing the effectiveness of MSCs and then had a deeply talk with our PIs.
More.

During mid phage of our project, we devoted ourselves to study and investigate other aspects connected to our project including ethics, law and regulation, safety, product analysis including intellectual property rights and so on by literature studying, interview and questionnaire, attending Cell Therapy Annual Meeting, etc.

Time flies. It is almost the end phage of the project this year, but we don't want to stop here. We can do more and better! We have done a lot of researches and had many activities during the project and we admit that there is such a large room for us to improve. We have no time to finish them in this year but we draw a discussion of Room for Improvement for the teams next year.

Get more information from our story page.